Investor Relations Roundtable

The T2B Investor Relations Roundtable empowers biopharma communicators to navigate the complex investor landscape and integrate IR seamlessly into broader corporate affairs strategies. Supporting professionals across all levels, the roundtable fosters collaboration and equips members with tools to enhance trust, credibility, and effective communication with the IR community and beyond.

Roundtable objectives

  • Facilitate knowledge-sharing to effectively engage investors, analysts, and other key stakeholders amid global market dynamics.
  • Develop frameworks for integrating IR into corporate communications, ensuring consistent and cohesive messaging.
  • Align evolving corporate affairs priorities with IR considerations spanning crisis communications, critical data readouts, ESG reporting, and expanding investor bases.
  • Strengthen T2B’s programming with IR-focused resources and connections that address real-world challenges and opportunities.
Chair
Deborah Elson

Deborah Elson

Senior Director, Corporate Communications and Investor Relations

Tonix Pharmaceuticals

Returning roundtable members

David Connolly

David Connolly

VP, IR and Corporate Communications

Rhythm Pharmaceuticals

Elizabeth Higgins

Elizabeth Higgins

Former Senior Director, Communications and Investor Relations

Astria Therapeutics

Chief of Staff / PM
Demet Durak

Demet Durak

Executive Assistant to the CEO

Vericel Corporation

“With investor relations and corporate communications intertwined more than ever in biotech to shape positioning and enhance credibility, I am pleased to collaborate with others to advance learning and connectivity that strengthen our IR savvy.”

Deborah Elson

Senior Director of Corporate Communications and Investor Relations, Tonix Pharmaceuticals

Interested in joining this roundtable?

Why join

  • Leverage your background and experience in biopharma investor relations into a forum for relevant conversations and sharing insights with your colleagues in the industry.
  • Work collaboratively in determining how best to address investor relations amid real-world challenges and evolving global market dynamics.
  • Play a role in developing frameworks and best practices for the biopharma industry on how to integrate investor relations into broader communications strategy.
  • Build meaningful connections and elevate your reputation as an investor relations thought leader within T2B’s community of communicators.

Eligibility requirements

Applicants must have:

  • A basic understanding of and experience in biopharma investor relations with current or prior experience on the agency, corporate (in-house), or consulting side.
  • The ability to volunteer 3-5 hours/month to co-create quarterly IR events and monthly resources for the broader T2B community.
  • The commitment to actively participate in quarterly roundtable meetings as well as contribute ideas and feedback.
  • An active T2B Pro membership.

Apply for a spot on the Investor Relations Roundtable

Applications are closed and will reopen in April 2026. Each member term is for one calendar year.